PROQR THERAPEUTICS NV (PRQR)
NL0010872495 - Common Stock
ProQR Announces Third Quarter 2024 Operating and Financial Results
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to...
Investors Snag PRQR 9.7% Cheaper Than Its Secondary Stock Offering
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to...
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to...
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to...
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...
PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024
PRQR stock results show that ProQR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ProQR Therapeutics (NASDAQ:PRQR) just reported results for the second quarter o...
ProQR Announces Second Quarter 2024 Operating and Financial Results
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
ProQR Announces First Quarter 2024 Operating and Financial Results
ProQR Announces First Quarter 2024 Operating and Financial Results
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to...
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to...
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to...
ProQR Announces Year End 2023 Operating and Financial Results
ProQR Announces Year End 2023 Operating and Financial Results
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting...
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional...
Thursday Sector Laggards: Drugs, Water Utilities
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett...
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome ...